Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
Alkermes (ALKS) Stock Price & Analysis
462 Followers
ALKS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.46 - $32.88
Previous Close$24.83
Volume106.14K
Average Volume (3M)1.79M
Market Cap
$4.21B
Enterprise Value$3.80B
Total Cash (Recent Filing)$773.49M
Total Debt (Recent Filing)$372.19M
Price to Earnings (P/E)9.8
Beta0.29
Next Earnings
Jul 24, 2024EPS Estimate
$0.68Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)2.54
Shares Outstanding169,221,311
10 Day Avg. Volume2,223,066
30 Day Avg. Volume1,791,151
Standard Deviation0.10
R-Squared0.05
Alpha0.00142
Financial Highlights & Ratios
Price to Book (P/B)3.78
Price to Sales (P/S)2.54
Price to Cash Flow (P/CF)9.80
P/FCF Ratio11.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.28
Enterprise Value/Gross Profit2.69
Enterprise Value/Ebitda7.32
Forecast
1Y Price Target
$35.67Price Target Upside43.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Alkermes News
PremiumPre-Earnings
Is ALKS a Buy, Before Earnings?
PremiumCompany Announcements
Alkermes Shareholders Approve Board Changes and Stock PlanBulls Say, Bears Say
Bulls Say
Commercial GrowthRobust commercial engine featuring Lybalvi, Aristada, and Vivitrol, expected to continue generating steady growth and revenues.
Pipeline DevelopmentSignificant potential for lead pipeline asset ALKS 2680 to disrupt the narcolepsy treatment paradigm.
Shareholder ValueGiven the low valuation, management has begun buying back shares.
Bears Say
Financial PerformanceThe 1Q24 results were soft, due primarily to an unusually high level of wholesaler destocking of Vivitrol, Aristada, and Lybalvi.
Market CompetitionHarmony Biosciences has entered the space as well, resulting in an even more crowded market.
Product DevelopmentALKS will not advance the 25mg dose in phase 2 due to lack of significant dose response and mild/transient visual disturbances observed at this level.
---
Ownership Overview
6.61% Insiders
36.57% Mutual Funds
34.35% Other Institutional Investors
22.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $20.46 and its highest was $32.88 in the past 12 months.
What is Alkermes’s market cap?
Currently, no data Available
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Jul 24, 2024 which is in 2 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on May 01, 2024. The company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.583 by -$0.153.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes pays a Notavailable dividend of $1.64 which represents an annual dividend yield of N/A. See more information on Alkermes dividends here
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is $0.68.
How many shares outstanding does Alkermes have?
Alkermes has 169,221,310 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.43 in its last earnings report, missing expectations of $0.583. Following the earnings report the stock price went down -2.16%.
Which hedge fund is a major shareholder of Alkermes?
Among the largest hedge funds holding Alkermes’s share is PRIMECAP Management Co. It holds Alkermes’s shares valued at 94M.
---
Alkermes Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.67 (43.48% Upside)
$35.67 (43.48% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 71.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.81%
12-Months-Change
Fundamentals
Return on Equity
42.85%
Trailing 12-Months
Asset Growth
10.46%
Trailing 12-Months
Company Description
Alkermes
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
ALKS Company Deck
---
ALKS Earnings Call
Q1 2024
0:00 / 0:00
---
ALKS Revenue Breakdown
55.31% Product sales, net
44.69% Manufacturing and royalty revenues
<0.01% Research and development revenue
0.00% License revenue
---
ALKS Stock 12 Month Forecast
Average Price Target
$35.67
▲(43.48% Upside)
Technical Analysis
Best Analysts Covering ALKS
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+1.45%
assigned a buy rating 2 months ago
Copying Akash Tewari's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +1.45% per trade.
---